Synthetic peptide SVVYGLR upregulates cell motility and facilitates oral mucosal wound healing
Usually administered monthly or every 23 weeks, depending on the condition
monotherapy doses in the Phase 2 dose-finding trial spanned 0.3 mg to 4.5 mg, with 2.4 mg used in the CagriSema combination
MOTS-C MOTS-C Select options This product has multiple variants
Single peptide MOTS-C What it supports A mitochondrial peptide that helps the body use energy more efficiently supporting fat metabolism, healthy blood sugar response, and stronger endurance during exercise
This powerful compound has been found to stimulate the proliferation and migration of various skin cells, including keratinocytes, fibroblasts, and endothelial cells, which are crucial for the wound healing process